CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
Globe Newswire•27/10/2026•08:00 ET
0
Key Highlights
- ➤EU CTA approval clears ASCEND Phase 1/2 trial of CMP-002 in SYNGAP1 disorder
- ➤CAMP4 (CAMP) plans first-patient dosing in 4Q 2026
- ➤ASCEND global trial footprint now includes the EU, UK, Australia, and Argentina
- ➤CMP-002 targets SYNGAP1 expression; no approved disease-modifying therapies currently exist
Expert Statements
Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4
“CTA approval in the European Union, following our clearances in the United Kingdom, Australia, and Argentina, expands the planned global footprint of ASCEND, our first-in-human trial of CMP-002 for SYNGAP1-related disorder, and gives more families the opportunity to participate closer to home”
Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4
“We remain focused in the near term on enrolling the ASCEND trial to advance CMP-002 for patients who currently have no approved disease-modifying treatment options.”
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002
Company on track to initiate ASCEND clinical trial in 4Q 2026
Get started
Create a free account to read the full story.